AI Terminal
DIACEUTICS PLC
Share Issue/Capital Change • Jul 29, 2024
7596_dirs_2024-07-29_43f89415-d679-4664-81ce-06da4fb27aa1.html
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1122Y
Diaceutics PLC
29 July 2024
Diaceutics PLC
Issue of Share Options/PDMR Shareholdings
Belfast and London, 29 July 2024- Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces the issue of 1,494,051 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP") on 23 July 2024. These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.
Share Options were granted as to PDMRs follows:
| Name | Number of Share Options granted | Total no. of ordinary shares under option post grant | % of existing issued share capital | Effective Grant date |
| Ryan Keeling, CEO | 236,250 | 581,947 | 0.69% | 23 July 2024 |
| Nick Roberts, CFO | 168,750 | 327,622 | 0.39% | 23 July 2024 |
| Julie Browne, COO and PDMR | 76,631 | 245,678 | 0.29% | 23 July 2024 |
| Jordan Clark, CDO and PDMR | 74,502 | 190,242 | 0.22% | 23 July 2024 |
| Susanne Munksted, CPO and PDMR | 74,647 | 284,829 | 0.34% | 23 July 2024 |
| Jillian Beggs, CCO and PDMR | 72,844 | 129,548 | 0.15% | 23 July 2024 |
A further 790,927 Share Options were granted to a total of 53 other employees.
The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth during the Performance Period in Total Shareholder Return ("TSR"), the revenue Compound Annual Growth Rate ("CAGR") and recurring revenue. The average mid-market closing share price in the three days prior to the issue of the Share Options was £1.33. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.
Following this grant, the total number of share options outstanding in the Company is 4,711,454 representing approximately 5.56% of its current issued share capital of 84,720,076.
Enquiries:
| Diaceutics PLC | |
| Nick Roberts, Chief Financial Officer | Tel: +44 (0)28 9040 6500 [email protected] |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison Nick Harland Kate Hanshaw |
|
| Alma Strategic Communications | Tel: +44(0)20 3405 0205 |
| Caroline Forde, Kinvara Verdon Kieran Breheny |
[email protected] |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a. | Name | Ryan Keeling | ||||
| 2 | Reason for notification | |||||
| a. | Position/Status | Chief Executive Officer | ||||
| b. | Initial notification/ Amendment |
Initial | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a. | Name | Diaceutics PLC | ||||
| b. | LEI | 213800VEWQBB39ZB8J81 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a. | Description of the financial instrument, type of instrument Identification Code |
Options over new ordinary shares of 0.2 p each ISIN: GB00BJQTGV64 |
||||
| b. | Nature of the transaction | Grant of share options | ||||
| c. | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| Exercise price of 0.2p per share | 236,250 | |||||
| e. | Date of the transaction | 23 July 2024 | ||||
| f. | Place of the transaction | Outside a trading venue |
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a. | Name | Nick Roberts | ||||
| 2 | Reason for notification | |||||
| a. | Position/Status | Chief Finance Officer | ||||
| b. | Initial notification/ Amendment |
Initial | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a. | Name | Diaceutics PLC | ||||
| b. | LEI | 213800VEWQBB39ZB8J81 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a. | Description of the financial instrument, type of instrument Identification Code |
Options over new ordinary shares of 0.2 p each ISIN: GB00BJQTGV64 |
||||
| b. | Nature of the transaction | Grant of share options | ||||
| c. | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| Exercise price of 0.2p per share | 168,750 | |||||
| e. | Date of the transaction | 23 July 2024 | ||||
| f. | Place of the transaction | Outside a trading venue |
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a. | Name | Julie Browne | ||||
| 2 | Reason for notification | |||||
| a. | Position/Status | Chief Operations Officer | ||||
| b. | Initial notification/ Amendment |
Initial | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a. | Name | Diaceutics PLC | ||||
| b. | LEI | 213800VEWQBB39ZB8J81 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a. | Description of the financial instrument, type of instrument Identification Code |
Options over new ordinary shares of 0.2 p each ISIN: GB00BJQTGV64 |
||||
| b. | Nature of the transaction | Grant of share options | ||||
| c. | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| Exercise price of 0.2p per share | 76,631 | |||||
| e. | Date of the transaction | 23 July 2024 | ||||
| f. | Place of the transaction | Outside a trading venue |
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a. | Name | Jordan Clark | ||||
| 2 | Reason for notification | |||||
| a. | Position/Status | Chief Data Officer | ||||
| b. | Initial notification/ Amendment |
Initial | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a. | Name | Diaceutics PLC | ||||
| b. | LEI | 213800VEWQBB39ZB8J81 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a. | Description of the financial instrument, type of instrument Identification Code |
Options over new ordinary shares of 0.2 p each ISIN: GB00BJQTGV64 |
||||
| b. | Nature of the transaction | Grant of share options | ||||
| c. | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| Exercise price of 0.2p per share | 74,502 | |||||
| e. | Date of the transaction | 23 July 2024 | ||||
| f. | Place of the transaction | Outside a trading venue |
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a. | Name | Susanne Munksted | ||||
| 2 | Reason for notification | |||||
| a. | Position/Status | Chief Precision Medicine Officer | ||||
| b. | Initial notification/ Amendment |
Initial | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a. | Name | Diaceutics PLC | ||||
| b. | LEI | 213800VEWQBB39ZB8J81 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a. | Description of the financial instrument, type of instrument Identification Code |
Options over new ordinary shares of 0.2 p each ISIN: GB00BJQTGV64 |
||||
| b. | Nature of the transaction | Grant of share options | ||||
| c. | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| Exercise price of 0.2p per share | 74,647 | |||||
| e. | Date of the transaction | 23 July 2024 | ||||
| f. | Place of the transaction | Outside a trading venue |
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a. | Name | Jillian Beggs | ||||
| 2 | Reason for notification | |||||
| a. | Position/Status | Chief Commercial Officer | ||||
| b. | Initial notification/ Amendment |
Initial | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a. | Name | Diaceutics PLC | ||||
| b. | LEI | 213800VEWQBB39ZB8J81 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a. | Description of the financial instrument, type of instrument Identification Code |
Options over new ordinary shares of 0.2 p each ISIN: GB00BJQTGV64 |
||||
| b. | Nature of the transaction | Grant of share options | ||||
| c. | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| Exercise price of 0.2p per share | 72,844 | |||||
| e. | Date of the transaction | 23 July 2024 | ||||
| f. | Place of the transaction | Outside a trading venue |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBVLLLZDLBBBD